Bayer acquisition plans
This article was originally published in The Tan Sheet
Bayer is not turning away from pursuing growth in the consumer segment and will continue to look for "useful and value-adding transactions in our OTC portfolio," CEO Werner Wenning maintained during a March 24 conference call on the firm's plans to merge its existing pharmaceuticals division with Berlin-based Schering AG. Bayer announced a $17.47 bil. "white knight" bid for the specialty pharmaceutical firm March 23, thwarting a hostile acquisition attempt from Merck. The move follows existing strategy, Wenning said. "We always pointed out that it is our strategy to strengthen the specialty products business of our pharma division and expand our global position in the OTC business...
You may also be interested in...
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.